Noticias Nuvectis Pharma Inc - NVCT | Acciones NASDAQ | ADVFN

US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Nuvectis Pharma Inc (NVCT)

6.35

0.01

(0.16%)

Al cierre: 05 Marzo 3:00PM

Delayed by 15 minutes

6.35

0.00

( 0.00% )

Fuera de horario: 3:30PM

Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets

Precision oncology player Nuvectis Pharma receives a buy recommendation and price target with a significant premium from Lucid Capital Markets...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and...

gail

gail 4 meses hace

grabbed some on the dip

Monksdream

Monksdream 6 meses hace

Monksdream

Monksdream 8 meses hace

Monksdream

Monksdream 10 meses hace

Monksdream

Monksdream 1 año hace

NVCT 10Q due March 6

Monksdream

Monksdream 1 año hace

conix

conix 3 años hace

NVCT HIGHLIGHTS:

*Recently completed Initial Public Offering - $5.00 Per share
*2 Precision Cancer medicines in development - ovarian and triple negative breast
*Data flow throughout 2022
*CEO with multiple success stories in life science sector to $billion dollar market caps
*Analysts project a $66 billion precision medicines market for 2021; In 6 years, this number is expected to top $140 billion

Nuvectis Pharma Inc - Company Background:

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates: NXP800, a clinical-stage HSF1 pathway inhibitor currently in a Phase 1 study in patients with advanced solid tumors, and NXP900, a novel SRC/YES1 kinase inhibitor currently in preclinical development with IND-enabling studies ongoing.

Market Capitalization: $225 million
Range - 52 week: $3.08 - $20.75
Current Price: $20.44
Trades on: Nasdaq Capital Market
Ticker Symbol: NVCT

website: nuvectis.com

TheFinalCD

TheFinalCD 3 años hace

wow from $3 to almost $21

ipo_dude

ipo_dude 3 años hace

TheFinalCD

TheFinalCD 3 años hace

WOW $7 MOVE 3-10

CONGRAT$ NVCT

spindog

spindog 3 años hace

I feel the same

kkballa

kkballa 3 años hace

Nuvectis Pharma

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones